Moderna Weighted Average Shares Trend from 2010 to 2022

MRNA
 Stock
  

USD 155.54  5.59  3.73%   

Moderna Weighted Average Shares is increasing over the years with slightly volatile fluctuation. Weighted Average Shares is expected to dwindle to about 339.6 M. From 2010 to 2022 Moderna Weighted Average Shares quarterly data regression line had arithmetic mean of 155,803,734 and slope of  30,333,291. Moderna Consolidated Income is projected to increase significantly based on the last few years of reporting. The past year's Consolidated Income was at 12.2 Billion. The current year Earning Before Interest and Taxes EBIT is expected to grow to about 14.3 B, whereas Preferred Dividends Income Statement Impact is forecasted to decline to about 19.1 M.
  
Refresh
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna main balance sheet or income statement drivers, such as Direct Expenses of 2.8 B, Consolidated Income of 13.2 B or Cost of Revenue of 2.1 B, as well as many exotic indicators such as Long Term Debt to Equity of 0.0349, Calculated Tax Rate of 7.29 or PPandE Turnover of 25.92. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules. It can also supplement various Moderna Technical models. Additionally, see the analysis of Moderna Correlation against competitors.

Moderna Quarterly Weighted Average Shares

402 Million

Share

Moderna Weighted Average Shares Breakdown

Showing smoothed Weighted Average Shares of Moderna with missing and latest data points interpolated. The weighted average number of shares or units issued and outstanding that are used by the company to calculate [EPS]; determined based on the timing of issuance of shares or units in the period.Moderna's Weighted Average Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 405.45 M10 Years Trend
Increasing
Slightly volatile
 Weighted Average Shares 
Share
      Timeline 

Moderna Weighted Average Shares Regression Statistics

Arithmetic Mean 155,803,734
Geometric Mean 108,112,121
Coefficient Of Variation 93.28
Mean Deviation 127,906,138
Median 60,747,426
Standard Deviation 145,333,292
Range 342,252,574
R-Value 0.81
R-Squared 0.66
Significance 0.00073072
Slope 30,333,291

Moderna Weighted Average Shares History

201764.5 M
201881.1 M
2019331 M
2020381 M
2021403 M
2022339.6 M

Other Fundumenentals of Moderna

Moderna Weighted Average Shares component correlations

About Moderna Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moderna income statement, its balance sheet, and the statement of cash flows. Moderna investors use historical funamental indicators, such as Moderna's Weighted Average Shares, to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moderna Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Weighted Average Shares403 M339.6 M
Weighted Average Shares Diluted431 M357 M
Average Assets18.6 B20.1 B
Average Equity8.7 B9.4 B
Invested Capital Average4.1 B4.4 B
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC Merck Co., Inc. Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Limited Carisma Therapeutics, Inc. Metagenomi, Inc. the Defense Advanced Research Projects Agency Biomedical Advanced Research and Development Authority Institute for Life Changing Medicines and The Bill Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moderna Correlation against competitors. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
59.6 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.